Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 4/20 | 0.33 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670505 | 0.92 | PRKD1 (0.34) | PRKD1KARS1KITPRKD2 | |
| SCHEMBL19706209 | 0.91 | SMPD3 (0.34) | HRH3KCNH2PRKD1 | |
| SCHEMBL19670635 | 0.87 | PRKD1 (0.35) | PRKD1KARS1PRKD2 | |
| SCHEMBL19706213 | 0.85 | PRKD1 (0.33) | HRH3PRKD1PDE10AKARS1 | |
| SCHEMBL19670237 | 0.84 | PRKD1 (0.33) | PRKD1KARS1 | |
| SCHEMBL19706211 | 0.83 | SMN1; SMN2 (0.36) | PRKD1PDE10AKARS1 | |
| SCHEMBL16754628 | 0.83 | HPGDS (0.41) | HRH3KCNH2MAPTCDK4CDK6 | |
| SCHEMBL19670481 | 0.80 | KARS1 (0.41) | HRH3MAPTPRKD1KARS1 | |
| SCHEMBL19670367 | 0.80 | CCNC (0.34) | — | |
| SCHEMBL19670673 | 0.79 | JAK3 (0.33) | KCNH2MTORUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HRH3 2288/4885KCNH2 4052/4885MAPT 267/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | HRH3 2288/4885KCNH2 4052/4885MAPT 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.